We are medtech company based in San Diego that is poised to disrupt the field of chronic pain. Using our proprietary therapy and novel mechanism, we can deliver non-invasive therapy that reduces pain in minutes upon the first application, specially in refractory patients. We are submitting for FDA 510(k) approval in November with approval expected in early February. Our Scientific Advisory Board contains some of the leading pain specialists in the country, including Dr. Leo Kapural. We believe our therapy will be a first line therapy to treat patients dealing with chronic neuropathic pain. With an initial addressable market of $22B, we expect to make a major impact in the opioid crisis in America. We are raising a Series A round of $12M. We have soft circled approximately $5M from existing investors and a $2B+ public Pharma company that focuses on pain.